
Relapsed/refractory acute myeloid leukemia (AML)- Pipeline Insight, 2024
Description
Relapsed/refractory acute myeloid leukemia (AML)- Pipeline Insight, 2024
DelveInsight’s, “Relapsed/refractory acute myeloid leukemia (AML)- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Relapsed/refractory acute myeloid leukemia (AML): Overview
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. The prognosis of relapsed acute myeloid leukemia (AML) is poor and treatment is challenging. The signs and symptoms of acute myeloid leukemia (AML) are common to other, less serious illnesses. It is common for people with AML to feel a loss of well-being because of the underproduction of normal bone marrow cells. Symptoms of a low red blood cell count (called “anemia”) include: Fatigue, weakness, shortness of breath during normal physical activities, lightheadedness, dizziness or faintness, headaches and pale complexion. Other general symptoms of AML include: Loss of appetite, unexplained weight loss, discomfort in bones or joints, fullness or swelling in the abdomen, due to an enlarged spleen or liver. While the most potent treatment modality for patients who achieve a complete remission after relapse is still allogeneic haematopoietic cell transplantation (allo-HCT), both transplant-related mortality and relapse rates are high and many patients are not candidates for this approach. After a few decades of relative stasis in this field, a large number of novel approaches have become available to tackle this highly fatal disease. While cure of relapsed/refractory AML without allo-HCT is currently unlikely, treatments are becoming less toxic and remissions are lasting longer. The management of acute myeloid leukaemia (AML) relapse in adults continues to remain a major therapeutic challenge despite the increasing availability of novel agents including targeted therapies. When considering treatment options for patients with relapsed/refractory AML, patient- and disease-related factors [e.g., age, comorbidities, performance status, cytogenetic and molecular abnormalities, prior lines of chemotherapy, history of prior allogeneic haematopoietic cell transplant (allo-HCT), and time to relapse after previous complete remission (CR)] should be carefully evaluated.
""Relapsed/refractory acute myeloid leukemia (AML)- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape is provided which includes the disease overview and Relapsed/refractory acute myeloid leukemia (AML) treatment guidelines. The assessment part of the report embraces, in depth Relapsed/refractory acute myeloid leukemia (AML) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed/refractory acute myeloid leukemia (AML) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed/refractory acute myeloid leukemia (AML) R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed/refractory acute myeloid leukemia (AML).
This segment of the Relapsed/refractory acute myeloid leukemia (AML) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs
- APG-2575: Ascentage Pharma
- CLN 049: Cullinan Oncology
- Lanraplenib: Kronos Bio
Further product details are provided in the report……..
Relapsed/refractory acute myeloid leukemia (AML): Therapeutic Assessment
This segment of the report provides insights about the different Relapsed/refractory acute myeloid leukemia (AML) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Relapsed/refractory acute myeloid leukemia (AML)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Relapsed/refractory acute myeloid leukemia (AML): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed/refractory acute myeloid leukemia (AML) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed/refractory acute myeloid leukemia (AML) drugs.
Relapsed/refractory acute myeloid leukemia (AML) Report Insights
- Relapsed/refractory acute myeloid leukemia (AML) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Relapsed/refractory acute myeloid leukemia (AML) drugs?
- How many Relapsed/refractory acute myeloid leukemia (AML) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed/refractory acute myeloid leukemia (AML)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsed/refractory acute myeloid leukemia (AML) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Relapsed/refractory acute myeloid leukemia (AML) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ascentage Pharma
- Cullinan Oncology
- Kronos Bio
- Maxinovel Pharmaceuticals
- AB Science
- CicloMed
- Karyopharm Therapeutics
- Antengene Corporation
- GlycoMimetics
- Servier
- Novartis
- ImmunoGen
- APG-2575
- CLN 049
- Lanraplenib
- MAX-40279-01
- AB8939
- Fosciclopirox
- KPT-9274
- Uproleselan
- S65487
- IMGN632
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Relapsed/refractory acute myeloid leukemia (AML): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Relapsed/refractory acute myeloid leukemia (AML)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- Comparative Analysis
- APG-2575: Ascentage Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CLN 049: Cullinan Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Relapsed/refractory acute myeloid leukemia (AML) Key Companies
- Relapsed/refractory acute myeloid leukemia (AML) Key Products
- Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
- Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
- Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
- Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
- Relapsed/refractory acute myeloid leukemia (AML) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.